INTRODUCTION: Malignant gastric outlet obstruction (GOO) is a common, debilitating and frequently pre-terminal symptom of intra-abdominal malignancies. Traditional 'gold standard' treatment has been palliative surgical gastro-enterostomy. Over the past two decades, use of self-expanding metallic stents (SEMSs) to relieve malignant GOO has become first-line treatment. We present the results from a single district general hospital in the UK in which malignant GOO was treated with SEMSs over a six-year period. METHODS: All patients who underwent palliative stenting for malignant gastro-duodenal tumours in our centre for six years up to January 2013 were assessed retrospectively. Outcomes were assessed with regard to: technical and clinical success; return to oral nutrition; prevalence of complications and re-intervention; and overall survival. RESULTS: Thirty-two stents were implanted in 29 patients. Technical success was 100%. Clinical success and return to oral nutrition were both 91%. The prevalence of complications was 16%. The prevalence of re-intervention was 13%. Mean survival was 91 (range, 5-392) days. Median wait from decision to implant a stent to stent implantation was 1 (range, 0-14) day. Overall, 25 covered and nine uncovered stents were implanted. CONCLUSION: Stent implantation for GOO in this patient group is an established and preferable alternative to surgical intervention. Much of the treatment for malignancies of the upper gastrointestinal tract has now been centralised. Our data showed comparable results with published data for these procedures, with a high prevalence of success and low prevalence of major complications. It is of considerable benefit to these patients not to have to travel to a regional centre for stent implantation.
INTRODUCTION:Malignant gastric outlet obstruction (GOO) is a common, debilitating and frequently pre-terminal symptom of intra-abdominal malignancies. Traditional 'gold standard' treatment has been palliative surgical gastro-enterostomy. Over the past two decades, use of self-expanding metallic stents (SEMSs) to relieve malignant GOO has become first-line treatment. We present the results from a single district general hospital in the UK in which malignant GOO was treated with SEMSs over a six-year period. METHODS: All patients who underwent palliative stenting for malignant gastro-duodenal tumours in our centre for six years up to January 2013 were assessed retrospectively. Outcomes were assessed with regard to: technical and clinical success; return to oral nutrition; prevalence of complications and re-intervention; and overall survival. RESULTS: Thirty-two stents were implanted in 29 patients. Technical success was 100%. Clinical success and return to oral nutrition were both 91%. The prevalence of complications was 16%. The prevalence of re-intervention was 13%. Mean survival was 91 (range, 5-392) days. Median wait from decision to implant a stent to stent implantation was 1 (range, 0-14) day. Overall, 25 covered and nine uncovered stents were implanted. CONCLUSION: Stent implantation for GOO in this patient group is an established and preferable alternative to surgical intervention. Much of the treatment for malignancies of the upper gastrointestinal tract has now been centralised. Our data showed comparable results with published data for these procedures, with a high prevalence of success and low prevalence of major complications. It is of considerable benefit to these patients not to have to travel to a regional centre for stent implantation.
Authors: Mouen Khashab; Ahmad S Alawad; Eun Ji Shin; Katherine Kim; Nicolas Bourdel; Vikesh K Singh; Anne Marie Lennon; Susan Hutfless; Reem Z Sharaiha; Stuart Amateau; Patrick I Okolo; Martin A Makary; Christopher Wolfgang; Marcia Irene Canto; Anthony N Kalloo Journal: Surg Endosc Date: 2013-01-09 Impact factor: 4.584
Authors: Jorge M Canena; Ana C Lagos; Inês N Marques; Sara D Patrocínio; Miguel G Tomé; Manuel A Liberato; Carlos M Romão; António P Coutinho; Pedro M Veiga; Beatriz C Neves; Hélder D Além; José A Gonçalves Journal: Eur J Gastroenterol Hepatol Date: 2012-07 Impact factor: 2.566
Authors: Manju D Chandrasegaram; Guy D Eslick; Clare O Mansfield; Han Liem; Mark Richardson; Sulman Ahmed; Michael R Cox Journal: Surg Endosc Date: 2011-09-05 Impact factor: 4.584
Authors: Michael Piesman; Richard A Kozarek; John J Brandabur; Douglas K Pleskow; Ram Chuttani; Viktor E Eysselein; William B Silverman; John J Vargo; Irving Waxman; Marc F Catalano; Todd H Baron; Willis G Parsons; Adam Slivka; David L Carr-Locke Journal: Am J Gastroenterol Date: 2009-08-25 Impact factor: 10.864
Authors: Suzanne M Jeurnink; Casper H J van Eijck; Ewout W Steyerberg; Ernst J Kuipers; Peter D Siersema Journal: BMC Gastroenterol Date: 2007-06-08 Impact factor: 3.067
Authors: Rajesh Krishnamoorthi; Shivanand Bomman; Petros Benias; Richard A Kozarek; Joyce A Peetermans; Edmund McMullen; Ornela Gjata; Shayan S Irani Journal: Endosc Int Open Date: 2022-06-10